Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866051 | 0.85 | TRPC5 (0.38) | PIK3C2BMAPTKDM4EL3MBTL1KMT2A | |
| SCHEMBL8255746 | 0.83 | PIK3C2B (0.43) | PIK3C2BTSHRMAPTKDM4EL3MBTL1 | |
| SCHEMBL12532539 | 0.83 | KDM4E (0.34) | PIK3C2BTSHRMAPTKDM4EL3MBTL1 | |
| SCHEMBL8283860 | 0.77 | MEN1 (0.40) | MAPTKDM4EKMT2AGAAMEN1 | |
| SCHEMBL4860783 | 0.75 | ALDH1A1 (0.38) | MAPTKDM4EKMT2AMEN1RAB9A | |
| SCHEMBL8258425 | 0.75 | PIK3C2B (0.43) | PIK3C2BTSHRMAPTKDM4EL3MBTL1 | |
| SCHEMBL8256125 | 0.75 | PIK3C2B (0.46) | PIK3C2BTSHRMAPTKDM4EL3MBTL1 | |
| SCHEMBL4857710 | 0.70 | TRPC5 (0.39) | MAPTKDM4EL3MBTL1KMT2AMEN1 | |
| SCHEMBL4860778 | 0.70 | TRPC5 (0.39) | TSHRMAPTKDM4EL3MBTL1KMT2A | |
| SCHEMBL4856850 | 0.70 | TRPC5 (0.40) | TSHRMAPTKDM4EL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951704-B1 | 1,3-DIHYDRO-BENZIMIDAZOL-2-YLIDENE AMINES USEFUL FOR THE TREATMENT OR PREVENTION OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| US-7956196-B2 | the major cause of lower respiratory tract illness during infancy and childhood | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-06-07 | — | — | US | disclosed |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | JANSSEN SCIENCES IRELAND UC (IE) | 2008-06-19 | — | — | US | disclosed |
| WO-2006097534-A1 | 1,3-DIHYDRO-BENZIMIDAZOL-2-YLIDENE AMINES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, RTF2 | PIK3C2B 1353/4885TSHR 1965/4885MAPT 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.